Full-Time

Senior Manager

Website Product Specialist, Consumer/HCP IMM

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$124.5k - $236.5k/yr

Vernon Hills, IL, USA

Hybrid

Hybrid role; on-site at Mettawa, IL with some remote days.

Category
Product (1)
Required Skills
Agile
UI/UX Design
Product Management
SEO
A/B Testing
JIRA
Oracle
Google Analytics

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Requires a minimum of 10+ years of progressively increasing responsibility in a product management or equivalent role managing large, complex, direct response website(s)
  • Proven track record of launching successful web or mobile products
  • Understanding of software testing methodologies and software development life cycle process
  • In-depth knowledge of the product development and evaluation process. Exposure to Agile development a must
  • Experience developing business use cases and strategic planning
  • Understanding of A/B and Multi-variate test design and execution, and analytical tools
  • Comprehensive experience with UX design, customer research, and user experience best practices – including the creation of detailed, annotated wireframes
  • Knowledge of current web and mobile technologies, and familiarity with how the digital ecosystem is evolving
  • In depth knowledge and experience with commercial enterprise Content Management Systems (CMS) such as: Adobe Experience Cloud, SDL Tridion, OpenText, Oracle and Sitecore
  • Experience implementing SEO best practices
  • Knowledge of site analytics tools such as Adobe Analytics and/or Google Analytics
  • Requires strong collaboration and interpersonal skills to be effective managing through a highly matrixed organization
  • Skills required include business acumen, organizational assessment, creativity, interpersonal skills, and quantitative analytical abilities
  • Outstanding communicator and comfortable interacting with a diverse group of technical and non-technical people
  • Results-oriented, self-starter with passion for user experience, technology and the internet
  • A strategic mindset that allows you to prioritize projects, launches, and features, and balance immediate requirements with a long-term vision
  • Must have experience with personalization, 1:1 approaches/data capture techniques (ie. email, addressable media, dynamic web), application of legal/privacy terms & conditions
Responsibilities
  • Research current state: document data points, identify problem space and pain points with current Web processes and operating models
  • Run workshops with consumer of current processes
  • Design In Housing Pilots for Web Products and workstreams such as Testing, Personalization
  • Run pilots and report findings and performance
  • Author and publish new operating model playbook
  • Execute Change management
  • Socialize Deeper Site Operations Reporting Trends
  • Holistically manage consumer Site Tagging & Tagging Optimization
  • Manage Platform Governance (BTS collaboration & vendor alignment)
  • Act as SME for content optimization workstreams such as: SEO, Site Tagging, Analytics, Testing and Personalization
  • Define process flow for content optimization
  • Support project tracking process for Web channel activation
  • Mentor and manage team members who support the same franchise area
  • Manage the product development process and life cycle from inception to product delivery, growth, and eventual retirement
  • Work closely with Brand Marketing, Agency partners, data and analytics and other cross functional team members to drive new launches and enhancements and ensure that value propositions, messaging, and marketing activities address unique user needs/pain points
  • Monitor the release process and prioritize the placement of new products or enhancements in a release, balancing organizational objectives, product strategy, and market needs
  • Oversee organizational project plans tied to release schedule, identifying organizational impact resulting from changes to planned timeline and provide brand Governance leadership
  • Be hands-on with content authoring and MRP submission for key project types that are in-housed and enable elimination of hand offs and quick delivery for initiatives that are high priority
  • Account for platform or other related technology needs beyond current core platforms in place for Web that need to be established or introduced to achieve the benefits and allow for streamlined and efficient operations in the new model
  • Instantiate a Test and learn approach to adopt and modify over time key enhancements to process
  • Work with the external authoring agency resources and identify the appropriate mix of internal and external support
  • Implement and guide targeted personalization project implementations - enabling delivery of content that is relevant, most engaging driving next best action.
  • Measure the operations and stability of websites including assurance that the site is operating and optimized appropriately to operational standards.
  • Implement changes across the organization in an efficient, way that doesn’t impact key business priorities – sequence the rollout to account for key priorities
  • Define and support platform enhancements and foundational changes that support the strategy and direction of new operating models.
  • Understand the existing web product development business processes and marketing driven input from concept through to implementation.
  • Ensure familiarity and understanding of the Adobe Experience Cloud suite – including AEM, Target, Analytics and AAM/AEP.
  • Familiarity with process management tools including but not limited to: MS Project, Smartsheet, Jira, etc.
  • Ensure familiarity with best practice design principles including Mobile First design
  • Understand the release process and have familiarize with the prioritization processes and process for new products or enhancements and which require development team support or backend data/API updates
  • Enable new processes that create efficiency and agility and guide marketers and agencies in new ways of working
  • Collaborate effectively in a matrixed environment with Brand Marketing, Creative/CRM/Digital agencies, Media, Market Research, Analytics, Business Technology Solutions (BTS), Sales Operations, and Medical/Regulatory/Legal integrated business partners.
  • Partner closely with Marketing Operations and including Medical/Regulatory/Legal/Privacy partners to educate, lead and help AbbVie anticipate and balance organizational needs.
  • Troubleshoot roadblocks and identify creative and compliant solutions to facilitate forward motion of new initiatives.
  • Guide creative agencies and support from change management perspective to identify where ways of working and processes need to change.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.